Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 28 04:00PM ET
91.43
Dollar change
-1.36
Percentage change
-1.47
%
Index- P/E7.94 EPS (ttm)11.51 Insider Own0.01% Shs Outstand243.22M Perf Week-1.41%
Market Cap21.73B Forward P/E666.06 EPS next Y0.14 Insider Trans0.00% Shs Float237.70M Perf Month-4.54%
Income2.83B PEG- EPS next Q2.69 Inst Own17.86% Short Float1.27% Perf Quarter-5.61%
Sales6.89B P/S3.15 EPS this Y-88.69% Inst Trans12.40% Short Ratio4.20 Perf Half Y-24.24%
Book/sh88.48 P/B1.03 EPS next Y-97.03% ROA12.39% Short Interest3.01M Perf Year-30.13%
Cash/sh60.11 P/C1.52 EPS next 5Y- ROE14.51% 52W Range88.00 - 136.91 Perf YTD-13.37%
Dividend Est.- P/FCF4.52 EPS past 5Y- ROI13.35% 52W High-33.22% Beta0.24
Dividend TTM- Quick Ratio10.14 Sales past 5Y1073.42% Gross Margin90.66% 52W Low3.90% ATR (14)2.42
Dividend Ex-DateJun 02, 2022 Current Ratio10.37 EPS Y/Y TTM-75.06% Oper. Margin55.34% RSI (14)39.51 Volatility2.16% 2.27%
Employees4530 Debt/Eq0.01 Sales Y/Y TTM-66.16% Profit Margin41.08% Recom2.17 Target Price126.70
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-89.63% Payout0.00% Rel Volume0.87 Prev Close92.79
Sales Surprise6.65% EPS Surprise215.01% Sales Q/Q-72.05% EarningsNov 06 BMO Avg Volume716.67K Price91.43
SMA20-2.06% SMA50-8.08% SMA200-12.60% Trades Volume621,840 Change-1.47%
Date Action Analyst Rating Change Price Target Change
Feb-23-24Initiated BMO Capital Markets Outperform $127
Jan-05-24Initiated Oppenheimer Perform
Dec-01-23Downgrade JP Morgan Neutral → Underweight $106 → $99
Oct-16-23Downgrade HSBC Securities Buy → Hold $124 → $111
Jul-14-23Initiated HSBC Securities Buy $124
May-17-23Upgrade Redburn Neutral → Buy $165 → $170
Dec-15-22Upgrade BofA Securities Neutral → Buy $239
Aug-17-22Initiated Cowen Market Perform $177
Jul-13-22Upgrade SVB Leerink Mkt Perform → Outperform
Jul-06-22Resumed Canaccord Genuity Buy $192
Feb-27-24 05:45AM
Feb-26-24 12:29PM
10:27AM
Feb-23-24 01:00PM
Feb-14-24 06:35PM
06:07AM Loading…
Feb-08-24 06:07AM
05:45AM
Feb-04-24 06:56AM
Feb-02-24 02:39PM
Feb-01-24 06:30AM
Jan-31-24 06:45AM
Jan-25-24 09:55AM
Jan-24-24 11:30AM
Jan-22-24 06:45AM
06:45AM
11:30AM Loading…
Jan-17-24 11:30AM
Jan-09-24 04:16PM
07:37AM
07:12AM
07:09AM
06:52AM
06:45AM
06:45AM
Dec-28-23 12:00AM
Dec-24-23 05:34PM
Dec-21-23 08:00AM
Dec-19-23 12:31PM
09:12AM
08:35AM
Dec-18-23 01:15PM
10:06AM Loading…
10:06AM
05:50AM
Dec-15-23 12:02PM
Dec-12-23 03:04PM
06:45AM
Dec-08-23 10:13AM
Dec-05-23 07:59AM
Dec-01-23 05:32AM
Nov-28-23 01:34PM
01:34PM
Nov-21-23 09:04AM
05:37AM
Nov-14-23 04:17PM
Nov-09-23 10:01PM
Nov-07-23 08:39AM
05:13AM
Nov-06-23 04:30PM
04:21PM
04:03PM
01:40PM
12:48PM
12:13PM
12:13PM
11:56AM
11:00AM
10:57AM
09:34AM
09:04AM
08:48AM
08:41AM
08:06AM
07:48AM
06:48AM
06:45AM
Oct-31-23 07:12PM
06:54AM
06:47AM
Oct-29-23 05:35PM
Oct-28-23 06:50AM
Oct-26-23 04:29PM
02:50PM
10:38AM
08:26AM
07:02AM
06:50AM
06:45AM
Oct-25-23 07:00AM
Oct-23-23 11:30AM
09:50AM
06:45AM
Oct-20-23 12:08PM
10:31AM
Oct-19-23 09:59AM
06:45AM
Oct-18-23 01:00PM
Oct-17-23 10:17AM
Oct-16-23 04:06PM
03:32PM
07:00AM
04:18AM
03:59AM
03:30AM
03:13AM
03:00AM
Oct-12-23 07:00AM
Oct-11-23 05:30AM
Oct-06-23 03:00PM
08:40AM
Oct-05-23 11:05AM
Oct-04-23 01:35PM
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.